Updated: Verve plans first in-human base editing trial in the US after FDA lifts clinical hold

Katherine Lewin

News Reporter

Verve Therapeutics is planning to begin an in-human base editing trial in the US in patients with heterozygous familial hypercholesterolemia (HeFH) after the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Verve plans first in-human base editing trial in the US after FDA lifts clinical hold

Katherine Lewin

News Reporter

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Up­dat­ed: Verve plans first in-hu­man base edit­ing tri­al in the US af­ter FDA lifts clin­i­cal hold

Katherine Lewin

News Reporter

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Updated: Verve plans first in-human base editing trial in the US after FDA lifts clinical hold

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?